Fasiplon

Fasiplon
Clinical data
ATC code
  • none
Identifiers
IUPAC name
  • 6-Ethyl-7-methoxy-5-methyl-2-(5-methyl-[1,2,4]oxadiazol-3-yl)-imidazo[1,2-a]pyrimidine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H15N5O2
Molar mass273.296 g·mol−1
3D model (JSmol)
SMILES
  • CC1=NC(C2=CN3C(N=C(OC)C(CC)=C3C)=N2)=NO1
InChI
  • InChI=1S/C13H15N5O2/c1-5-9-7(2)18-6-10(11-14-8(3)20-17-11)15-13(18)16-12(9)19-4/h6H,5H2,1-4H3 ☒N
  • Key:MEBYKPLMXIRYRQ-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Fasiplon (RU 33203) is a nonbenzodiazepine anxiolytic drug from the imidazopyrimidine family of drugs.

Fasiplon binds strongly to benzodiazepine sites on the GABAA receptor and has similar anxiolytic effects in animals, but with less sedative or muscle relaxant action.[1] It was developed by a team at Roussel Uclaf in the 1990s[2]

References

  1. ↑ Tully WR, Gardner CR, Gillespie RJ, Westwood R (July 1991). "2-(oxadiazolyl)- and 2-(thiazolyl)imidazo[1,2-a]pyrimidines as agonists and inverse agonists at benzodiazepine receptors". Journal of Medicinal Chemistry. 34 (7): 2060–7. doi:10.1021/jm00111a021. PMID 1648620.
  2. ↑ US Patent 5869481 Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.